{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:34:16Z","timestamp":1794335656278,"version":"4.9.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T00:00:00Z","timestamp":1376352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"},{"start":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T00:00:00Z","timestamp":1376352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Dasatinib is a dual Abl\/Src tyrosine kinase inhibitor (TKI) designed as a prototypic short-acting BCR\u2013ABL-targeted TKI that inhibits BCR\u2013ABL with greater potency compared with imatinib, nilotinib, bosutinib, and ponatinib and has been shown to have potential immunomodulatory effects. Dasatinib is approved for the treatment of all phases of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to prior imatinib treatment and first-line treatment for CML in chronic phase. In this article, the development of dasatinib as a treatment for patients with CML is reviewed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This is a review of the relevant literature regarding dasatinib development in CML (2003\u20132013).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Dasatinib demonstrates efficacy against most BCR\u2013ABL mutations arising during imatinib therapy and is effective in treating patients with imatinib resistance due to other mechanisms. Randomized trial data show that first-line dasatinib provides superior responses compared with imatinib and enables patients to achieve early, deep responses correlated with improved longer-term outcomes. Dasatinib has a generally acceptable safety profile, with most adverse events (AEs) proving manageable and reversible. Cytopenias are commonly observed with dasatinib, and some nonhematologic AEs including pleural effusion have been consistently reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Dasatinib is an effective treatment option for patients with CML.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00432-013-1488-z","type":"journal-article","created":{"date-parts":[[2013,8,12]],"date-time":"2013-08-12T09:03:07Z","timestamp":1376298187000},"page":"1971-1984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients"],"prefix":"10.1007","volume":"139","author":[{"given":"Andreas","family":"Hochhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,13]]},"reference":[{"key":"1488_CR1","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","volume":"27","author":"JF Apperley","year":"2009","unstructured":"Apperley JF, Cortes JE, Kim DW et al (2009) Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START-A trial. J Clin Oncol 27:3472\u20133479","journal-title":"J Clin Oncol"},{"key":"1488_CR2","doi-asserted-by":"crossref","unstructured":"Baccarani M, Rosti G, Saglio G et al (2008) Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP). [abstract 450]. Blood 112","DOI":"10.1182\/blood.V112.11.450.450"},{"key":"1488_CR3","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013 June 28 [Epub ahead of print]"},{"key":"1488_CR4","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","volume":"114","author":"S Branford","year":"2009","unstructured":"Branford S, Melo JV, Hughes TP (2009) Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114:5426\u20135435","journal-title":"Blood"},{"key":"1488_CR5","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/1078-0432.CCR-07-4175","volume":"14","author":"M Brave","year":"2008","unstructured":"Brave M, Goodman V, Kaminskas E et al (2008) Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 14:352\u2013359","journal-title":"Clin Cancer Res"},{"key":"1488_CR6","unstructured":"Bristol-Myers Squibb (2013a) Open-label study evaluating dasatinib therapy discontinuation in patients with chronic phase chronic myeloid leukemia with stable complete molecular response (DASFREE). ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01850004. Accessed 6 June 2013"},{"key":"1488_CR7","unstructured":"Bristol-Myers Squibb (2013b) Phase IIb study of dasatinib versus imatinib in patients with CML-CP who have not achieved an early optimal response to imatinib (early switch). ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). http:\/\/clinicaltrials.gov\/show\/NCT01593254. Accessed 26 April 2013"},{"key":"1488_CR8","unstructured":"Bristol-Myers Squibb (2013c) Studying first line treatment of chronic myeloid leukemia (CML) in a real-world setting (SIMPLICITY). ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). http:\/\/clinicaltrials.gov\/show\/NCT01244750. Accessed 26 April 2013"},{"key":"1488_CR9","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1073\/pnas.0409770102","volume":"102","author":"MR Burgess","year":"2005","unstructured":"Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL (2005) Comparative analysis of two clinically active BCR\u2013ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 102:3395\u20133400","journal-title":"Proc Natl Acad Sci USA"},{"key":"1488_CR10","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1038\/sj.bjc.6604676","volume":"99","author":"Q Chang","year":"2008","unstructured":"Chang Q, Jorgensen C, Pawson T, Hedley DW (2008) Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer 99:1074\u20131082","journal-title":"Br J Cancer"},{"key":"1488_CR11","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","volume":"109","author":"J Cortes","year":"2007","unstructured":"Cortes J, Rousselot P, Kim DW et al (2007a) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207\u20133213","journal-title":"Blood"},{"key":"1488_CR12","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","volume":"110","author":"J Cortes","year":"2007","unstructured":"Cortes J, Jabbour E, Kantarjian H et al (2007b) Dynamics of BCR\u2013ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110:4005\u20134011","journal-title":"Blood"},{"key":"1488_CR13","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1038\/leu.2008.221","volume":"22","author":"J Cortes","year":"2008","unstructured":"Cortes J, Kim DW, Raffoux E et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22:2176\u20132183","journal-title":"Leukemia"},{"key":"1488_CR14","doi-asserted-by":"crossref","unstructured":"Cortes J, Talpaz M, Bixby D et al (2010a) A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. [abstract 210]. Blood 116","DOI":"10.1182\/blood.V116.21.210.210"},{"key":"1488_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Jones D, O\u2019Brien S et al (2010b) Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28:398\u2013404","journal-title":"J Clin Oncol"},{"key":"1488_CR16","unstructured":"Das J, Patmanabha R, Chen P et al (2005) Cyclic protein tyrosine kinase inhibitors. US patent number 006596746-B1. Patent issued July 22, 2003"},{"key":"1488_CR17","doi-asserted-by":"publisher","first-page":"6819","DOI":"10.1021\/jm060727j","volume":"49","author":"J Das","year":"2006","unstructured":"Das J, Chen P, Norris D et al (2006) 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem 49:6819\u20136832","journal-title":"J Med Chem"},{"key":"1488_CR18","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H de Lavallade","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS et al (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26:3358\u20133363","journal-title":"J Clin Oncol"},{"key":"1488_CR19","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1002\/cncr.27506","volume":"118","author":"M Defina","year":"2012","unstructured":"Defina M, Ippoliti M, Gozzetti A et al (2012) Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy. Cancer 118:5265\u20135269","journal-title":"Cancer"},{"key":"1488_CR20","doi-asserted-by":"publisher","first-page":"7304","DOI":"10.1158\/0008-5472.CAN-10-1543","volume":"70","author":"B Dewaele","year":"2010","unstructured":"Dewaele B, Floris G, Finalet-Ferreiro J et al (2010) Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res 70:7304\u20137314","journal-title":"Cancer Res"},{"key":"1488_CR21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley G et al (2003) BCR\u2013ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690\u2013698","journal-title":"Blood"},{"key":"1488_CR22","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408\u20132417","journal-title":"N Engl J Med"},{"key":"1488_CR23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1183\/09031936.00154210","volume":"38","author":"D Dumitrescu","year":"2011","unstructured":"Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S (2011) Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukemia. Eur Respir J 38:218\u2013220","journal-title":"Eur Respir J"},{"key":"1488_CR24","volume-title":"Sprycel\u00ae (dasatinib) [summary of product characteristics]","author":"European Medicines Agency","year":"2012","unstructured":"European Medicines Agency (2012) Sprycel\u00ae (dasatinib) [summary of product characteristics]. Bristol-Myers Squibb Pharma EEIG, Uxbridge, UK"},{"key":"1488_CR25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.healun.2012.06.002","volume":"31","author":"JC Fang","year":"2012","unstructured":"Fang JC, DeMarco T, Givertz MM et al (2012) World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult\u2014a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 31:913\u2013933","journal-title":"J Heart Lung Transplant"},{"key":"1488_CR26","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","volume":"30","author":"N Gali\u00e8","year":"2009","unstructured":"Gali\u00e8 N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493\u20132537","journal-title":"Eur Heart J"},{"key":"1488_CR27","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","volume":"109","author":"F Guilhot","year":"2007","unstructured":"Guilhot F, Apperley J, Kim DW et al (2007) Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109:4143\u20134150","journal-title":"Blood"},{"key":"1488_CR28","doi-asserted-by":"crossref","unstructured":"Guilhot F, Kantarjian HM, Shah NP et al (2010) Dasatinib (versus imatinib) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of safety and efficacy by use of baseline medications in the DASISION trial. [abstract 2295]. Blood 116","DOI":"10.1182\/blood.V116.21.2295.2295"},{"key":"1488_CR29","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, M\u00fcller MC, Hehlmann R et al (2012) Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096\u20132102","journal-title":"Leukemia"},{"key":"1488_CR30","doi-asserted-by":"publisher","first-page":"13283","DOI":"10.1073\/pnas.0702654104","volume":"104","author":"O Hantschel","year":"2007","unstructured":"Hantschel O, Rix U, Schmidt U et al (2007) The Btk tyrosine kinase is a major target of the Bcr\u2013Abl inhibitor dasatinib. Proc Natl Acad Sci USA 104:13283\u201313288","journal-title":"Proc Natl Acad Sci USA"},{"key":"1488_CR31","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M, European LeukemiaNet (2007) Chronic myeloid leukemia. Lancet 370:342\u2013350","journal-title":"Lancet"},{"key":"1488_CR32","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1471-2466-11-30","volume":"11","author":"JK Hennigs","year":"2011","unstructured":"Hennigs JK, Keller G, Baumann HJ et al (2011) Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 11:30","journal-title":"BMC Pulm Med"},{"key":"1488_CR33","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","volume":"14","author":"DK Hiwase","year":"2008","unstructured":"Hiwase DK, Saunders V, Hewett D et al (2008) Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 14:3881\u20133888","journal-title":"Clin Cancer Res"},{"key":"1488_CR34","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/leu.2009.299","volume":"24","author":"DK Hiwase","year":"2010","unstructured":"Hiwase DK, White DL, Powell JA et al (2010) Blocking cytokine signalling along with intense Bcr\u2013Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia 24:771\u2013778","journal-title":"Leukemia"},{"key":"1488_CR35","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","volume":"109","author":"A Hochhaus","year":"2007","unstructured":"Hochhaus A, Kantarjian HM, Baccarani M et al (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303\u20132309","journal-title":"Blood"},{"key":"1488_CR36","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/leu.2008.84","volume":"22","author":"A Hochhaus","year":"2008","unstructured":"Hochhaus A, Baccarani M, Deininger M et al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:1200\u20131206","journal-title":"Leukemia"},{"key":"1488_CR37","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F et al (2009a) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054\u20131061","journal-title":"Leukemia"},{"key":"1488_CR38","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1038\/leu.2009.156","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, M\u00fcller MC, Radich J et al (2009b) Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 23:1628\u20131633","journal-title":"Leukemia"},{"key":"1488_CR39","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4161\/cc.10.2.14537","volume":"10","author":"A Hochhaus","year":"2011","unstructured":"Hochhaus A, La Ros\u00e9e P, M\u00fcller MC, Ernst T, Cross NC (2011) Impact of BCR\u2013ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 10:250\u2013260","journal-title":"Cell Cycle"},{"key":"1488_CR40","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Shah NP, Cortes JE et al (2012a) Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year follow-up. [abstract 6504]. J Clin Oncol 30","DOI":"10.1200\/jco.2012.30.15_suppl.6504"},{"issue":"s1","key":"1488_CR41","first-page":"76","volume":"97","author":"A Hochhaus","year":"2012","unstructured":"Hochhaus A, Boqu\u00e9 C, Bradley Garelik MB et al (2012b) Molecular response kinetics and BCR\u2013ABL reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib versus imatinib: DASISION 3-year follow-up. [abstract 0192]. Haematologica 97(s1):76","journal-title":"Haematologica"},{"key":"1488_CR42","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1158\/0008-5472.CAN-06-3633","volume":"67","author":"F Huang","year":"2007","unstructured":"Huang F, Reeves K, Han X et al (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67:2226\u20132238","journal-title":"Cancer Res"},{"key":"1488_CR43","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S et al (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423\u20131432","journal-title":"N Engl J Med"},{"key":"1488_CR44","doi-asserted-by":"crossref","unstructured":"Jabbour E, Kantarjian HM, Quint\u00e1s-Cardama A et al (2011) Impact of dose reductions and interruptions due to adverse events (AEs) on efficacy in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) patients (pts) receiving either dasatinib (D) or imatinib (IM): analysis of the DASISION trial. [abstract 2768]. Blood 118","DOI":"10.1182\/blood.V118.21.2768.2768"},{"key":"1488_CR45","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H, Pasquini R, Hamerschlak N et al (2007) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109:5143\u20135150","journal-title":"Blood"},{"key":"1488_CR46","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/cncr.23238","volume":"112","author":"H Kantarjian","year":"2008","unstructured":"Kantarjian H, O\u2019Brien S, Shan J et al (2008) Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112:837\u2013845","journal-title":"Cancer"},{"key":"1488_CR47","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1002\/cncr.24504","volume":"115","author":"HM Kantarjian","year":"2009","unstructured":"Kantarjian HM, Pasquini R, L\u00e9vy V et al (2009a) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 115:4136\u20134147","journal-title":"Cancer"},{"key":"1488_CR48","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","volume":"113","author":"H Kantarjian","year":"2009","unstructured":"Kantarjian H, Cortes J, Kim DW et al (2009b) Phase 3 study of dasatinib 140 mg once daily versus 70\u00a0mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 113:6322\u20136329","journal-title":"Blood"},{"key":"1488_CR49","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260\u20132270","journal-title":"N Engl J Med"},{"key":"1488_CR50","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE et al (2012) Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 119:1123\u20131129 (republished with permission of the American Society of Hematology, permission conveyed through Copyright Clearance Center, Inc.)","journal-title":"Blood"},{"key":"1488_CR51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman MW, Herrgard S, Treiber DK et al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127\u2013132","journal-title":"Nat Biotechnol"},{"key":"1488_CR52","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","volume":"111","author":"JS Khorashad","year":"2008","unstructured":"Khorashad JS, Milojkovic D, Mehta P et al (2008) In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 111:2378\u20132381","journal-title":"Blood"},{"key":"1488_CR53","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/cncr.24155","volume":"115","author":"HJ Khoury","year":"2009","unstructured":"Khoury HJ, Guilhot F, Hughes T, Kim DW, Cortes JE (2009) Dasatinib treatment for Philadelphia chromosome-positive leukemias. Cancer 115:1381\u20131394","journal-title":"Cancer"},{"key":"1488_CR54","doi-asserted-by":"crossref","unstructured":"Khoury HJ, Cortes JE, Kantarjian H et al (2010) Safety and efficacy of dasatinib (DAS) vs. imatinib (IM) by baseline comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial. [abstract 3421]. Blood 116","DOI":"10.1182\/blood.V116.21.3421.3421"},{"key":"1488_CR55","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","volume":"116","author":"A Kreutzman","year":"2010","unstructured":"Kreutzman A, Juvonen V, Kairisto V et al (2010) Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 116:772\u2013782","journal-title":"Blood"},{"key":"1488_CR56","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/leu.2011.135","volume":"25","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Ladell K, Koechel C et al (2011) Expansion of highly differentiated CD8+\u00a0T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 25:1587\u20131597","journal-title":"Leukemia"},{"key":"1488_CR57","doi-asserted-by":"crossref","unstructured":"La Ros\u00e9e P, Martiat P, Leitner A et al (2013) Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol 2013 April 28 [Epub ahead of print]","DOI":"10.1007\/s00277-013-1769-2"},{"key":"1488_CR58","doi-asserted-by":"crossref","unstructured":"Laneuville P, Baccarani M, Cortes JE et al (2011) Analysis of patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: management and outcomes. [abstract 6605]. J Clin Oncol 29","DOI":"10.1200\/jco.2011.29.15_suppl.6605"},{"key":"1488_CR59","doi-asserted-by":"publisher","first-page":"e29828","DOI":"10.1371\/journal.pone.0029828","volume":"7","author":"NM Levinson","year":"2012","unstructured":"Levinson NM, Boxer SG (2012) Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS One 7:e29828","journal-title":"PLoS One"},{"key":"1488_CR60","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nchembio.332","volume":"6","author":"J Li","year":"2010","unstructured":"Li J, Rix U, Fang B et al (2010) A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6:291\u2013299","journal-title":"Nat Chem Biol"},{"key":"1488_CR61","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Francis YL, Chen P et al (2004) Discover of N-(2-Chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658\u20136661","journal-title":"J Med Chem"},{"key":"1488_CR62","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"D Marin","year":"2008","unstructured":"Marin D, Milojkovic D, Olavarria E et al (2008) European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112:4437\u20134444","journal-title":"Blood"},{"key":"1488_CR63","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","volume":"120","author":"D Marin","year":"2012","unstructured":"Marin D, Hedgley C, Clark RE et al (2012a) The predictive value of early molecular response in chronic phase CML patients treated with dasatinib first line therapy. Blood 120:291\u2013294","journal-title":"Blood"},{"key":"1488_CR64","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C et al (2012b) Assessment of BCR\u2013ABL1 transcript levels at 3\u00a0months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30:232\u2013238","journal-title":"J Clin Oncol"},{"key":"1488_CR65","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/bmt.2008.415","volume":"43","author":"D Mattei","year":"2009","unstructured":"Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A (2009) Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 43:967\u2013968","journal-title":"Bone Marrow Transplant"},{"key":"1488_CR66","doi-asserted-by":"crossref","unstructured":"Mauro MJ, Baccarani M, Cervantes F et al (2008) Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). [abstract 7009]. J Clin Oncol 26","DOI":"10.1200\/jco.2008.26.15_suppl.7009"},{"key":"1488_CR67","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","volume":"53","author":"VV McLaughlin","year":"2009","unstructured":"McLaughlin VV, Archer SL, Badesch DB et al (2009) ACCF\/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53:1573\u20131619 and Circulation 119:2250\u20132294","journal-title":"J Am Coll Cardiol"},{"key":"1488_CR68","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","volume":"125","author":"D Montani","year":"2012","unstructured":"Montani D, Bergot E, Gunther S et al (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125:2128\u20132137","journal-title":"Circulation"},{"key":"1488_CR69","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","volume":"114","author":"MC M\u00fcller","year":"2009","unstructured":"M\u00fcller MC, Cortes JE, Kim DW et al (2009) Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 114:4944\u20134953","journal-title":"Blood"},{"key":"1488_CR70","doi-asserted-by":"crossref","unstructured":"Mustjoki S, Rousselot P, Jalkanen S et al (2010) Dasatinib induces a rapid, dose-controllable mobilization of cytotoxic lymphocytes: a novel immunomodulatory effect associated with prolonged therapy responses in advanced leukemia. [abstract 1204]. Blood 116","DOI":"10.1182\/blood.V116.21.1204.1204"},{"key":"1488_CR71","doi-asserted-by":"crossref","unstructured":"Mustjoki S, Richter J, Barbany G et al (2011) Favorable therapeutic responses in newly diagnosed CML-CP patients induced by dasatinib are reflected at the CD34+CD38+\u00a0progenitor cell but not at the CD34+CD38-\u00a0stem cell level: results from randomized NordCML006 study. [abstract 784]. Blood 118","DOI":"10.1182\/blood.V118.21.784.784"},{"key":"1488_CR72","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/leu.2012.348","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Auvinen K, Kreutzman A et al (2013) Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 27:914\u2013924","journal-title":"Leukemia"},{"key":"1488_CR73","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology\u2122. Chronic myelogenous leukemia v.4.2013. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site"},{"key":"1488_CR74","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP et al (2005) In vitro activity of Bcr\u2013Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500\u20134505","journal-title":"Cancer Res"},{"key":"1488_CR75","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X et al (2009) AP24534, a pan-BCR\u2013ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401\u2013412","journal-title":"Cancer Cell"},{"key":"1488_CR76","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.leukres.2011.08.007","volume":"36","author":"EM Orlandi","year":"2011","unstructured":"Orlandi EM, Rocca B, Pazzano AS, Ghio S (2011) Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. Leuk Res 36:e4\u2013e6","journal-title":"Leuk Res"},{"key":"1488_CR77","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","volume":"110","author":"O Ottmann","year":"2007","unstructured":"Ottmann O, Dombret H, Martinelli G et al (2007) Dasatinib induces hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110:2309\u20132315","journal-title":"Blood"},{"key":"1488_CR78","doi-asserted-by":"crossref","unstructured":"Pemmaraju N, Kantarjian HM, Luthra R et al (2011) Results of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia (CML) in chronic phase (CP). [abstract 1700]. Blood 118","DOI":"10.1182\/blood.V118.21.1700.1700"},{"key":"1488_CR79","doi-asserted-by":"publisher","first-page":"21446","DOI":"10.1074\/jbc.M109.090043","volume":"285","author":"T Pene-Dumitrescu","year":"2010","unstructured":"Pene-Dumitrescu T, Smithall TE (2010) Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem 285:21446\u201321457","journal-title":"J Biol Chem"},{"key":"1488_CR80","first-page":"95","volume":"25","author":"L Philibert","year":"2011","unstructured":"Philibert L, Carzola C, Peyriere H et al (2011) Pulmonary arterial hypertension induced by dasatinib: positive reintroduction with nilotinib. [abstract 476]. Fundam Clin Pharmacol 25:95","journal-title":"Fundam Clin Pharmacol"},{"key":"1488_CR81","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/cncr.24734","volume":"116","author":"K Porkka","year":"2010","unstructured":"Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE (2010) Dasatinib 100\u00a0mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy in unaffected in patients who develop pleural effusion. Cancer 116:377\u2013386","journal-title":"Cancer"},{"key":"1488_CR82","doi-asserted-by":"publisher","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","volume":"66","author":"M Puttini","year":"2006","unstructured":"Puttini M, Coluccia AM, Boschelli F et al (2006) In vitro and in vivo activity of SKI-606, a novel Src\u2013Abl inhibitor, against imatinib-resistant Bcr\u2013Abl+\u00a0neoplastic cells. Cancer Res 66:11314\u201311322","journal-title":"Cancer Res"},{"key":"1488_CR83","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Cortes J (2009) Molecular biology of bcr\u2013abl1-positive chronic myeloid leukemia. Blood 113:1619\u20131630","journal-title":"Blood"},{"key":"1488_CR84","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O\u2019Brien S et al (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908\u20133914","journal-title":"J Clin Oncol"},{"key":"1488_CR85","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.3816\/CLM.2008.s.003","volume":"8","author":"A Quint\u00e1s-Cardama","year":"2008","unstructured":"Quint\u00e1s-Cardama A, Cort\u00e9s JE, Kantarjian H (2008) Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma 8:S82\u2013S88","journal-title":"Clin Lymphoma Myeloma"},{"key":"1488_CR86","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1002\/cncr.24257","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Ravandi F et al (2009a) Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115:2482\u20132490","journal-title":"Cancer"},{"key":"1488_CR87","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1002\/cncr.24432","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, De Souza Santos FP, Kantarjian H et al (2009b) Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure. Cancer 115:3935\u20133943","journal-title":"Cancer"},{"key":"1488_CR88","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","volume":"120","author":"JP Radich","year":"2012","unstructured":"Radich JP, Kopecky KJ, Appelbaum FR et al (2012) A randomized trial of dasatinib 100\u00a0mg versus imatinib 400\u00a0mg in newly diagnosed chronic-phase chronic myeloid\u00a0leukemia. Blood 120:3898\u20133905","journal-title":"Blood"},{"key":"1488_CR89","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.leukres.2008.09.026","volume":"33","author":"W Rasheed","year":"2009","unstructured":"Rasheed W, Flaim B, Seymour JF (2009) Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 33:861\u2013864","journal-title":"Leuk Res"},{"key":"1488_CR90","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","volume":"27","author":"S Redaelli","year":"2009","unstructured":"Redaelli S, Piazza R, Rostagno R et al (2009) Activity of bosutinib, dasatinib and nilotinib against 18 imatinib-resistant BCR\/ABL mutants. J Clin Oncol 27:469\u2013471","journal-title":"J Clin Oncol"},{"key":"1488_CR91","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, D\u00fcrnberger G et al (2007) Chemical proteomic profiles of the BCR\u2013ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and non kinase targets. Blood 110:4055\u20134063","journal-title":"Blood"},{"key":"1488_CR92","first-page":"349","volume":"93","author":"G Saglio","year":"2008","unstructured":"Saglio G, Dombret H, Rea D et al (2008) Dasatinib efficacy in patients with imatinib-resistant\/-intolerant chronic myeloid leukemia in blast phase: 24-month data from the START program. [abstract 0880]. Haematologica 93:349","journal-title":"Haematologica"},{"key":"1488_CR93","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S et al (2010a) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New Engl J Med 362:2251\u20132259","journal-title":"New Engl J Med"},{"key":"1488_CR94","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1002\/cncr.25123","volume":"116","author":"G Saglio","year":"2010","unstructured":"Saglio G, Hochhaus A, Goh YT et al (2010b) Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2\u00a0years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 116:3852\u20133861","journal-title":"Cancer"},{"key":"1488_CR95","doi-asserted-by":"crossref","unstructured":"Saglio G, Hochhaus A, Cortes JE et al (2010c) Safety and efficacy of dasatinib versus imatinib by baseline cardiovascular comorbidity in patients with chronic myeloid leukemia in chronic phase (CML-CP): analysis of the DASISION trial. [abstract 2286]. Blood 116","DOI":"10.1182\/blood.V116.21.2286.2286"},{"key":"1488_CR96","doi-asserted-by":"crossref","unstructured":"Saglio G, Kantarjian HM, Shah N et al (2012) Early response (molecular and cytogenetic) and long-term outcomes in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): exploratory analysis of DASISION 3-year data. [abstract 1675]. Blood 120","DOI":"10.1182\/blood.V120.21.1675.1675"},{"key":"1488_CR97","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2169\/internalmedicine.51.7472","volume":"51","author":"M Sano","year":"2012","unstructured":"Sano M, Saotome M, Urushida T et al (2012) Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-. Intern Med 51:2337\u20132340","journal-title":"Intern Med"},{"key":"1488_CR98","doi-asserted-by":"crossref","unstructured":"Schiffer CA, Cortes JE, Saglio G et al (2010a) Lymphocytosis following first-line treatment for CML in chronic phase with dasatinib is associated with improved responses: a comparison with imatinib. [abstract 358]. Blood 116","DOI":"10.1182\/blood.V116.21.358.358"},{"key":"1488_CR99","doi-asserted-by":"publisher","first-page":"15s","DOI":"10.1200\/JCO.2009.25.8616","volume":"28","author":"CA Schiffer","year":"2010","unstructured":"Schiffer CA, Cortes JE, Saglio G et al (2010b) Lymphocytosis following treatment with dasatinib with response and outcome. [abstract 6553]. J Clin Oncol 28:15s","journal-title":"J Clin Oncol"},{"key":"1488_CR100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4137\/CMO.S6413","volume":"4","author":"M Serpa","year":"2010","unstructured":"Serpa M, Sanabani SS, Bendit I et al (2010) Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy. Clin Med Insights Oncol 4:155\u2013162","journal-title":"Clin Med Insights Oncol"},{"key":"1488_CR101","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399\u2013401","journal-title":"Science"},{"key":"1488_CR102","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah NP, Skaggs BJ, Branford S et al (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR\u2013ABL mutations with altered oncogenic potency. J Clin Invest 117:2562\u20132569","journal-title":"J Clin Invest"},{"key":"1488_CR103","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kantarjian HM, Kim DW et al (2008a) Intermittent target inhibition with dasatinib 100\u00a0mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26:3204\u20133212","journal-title":"J Clin Oncol"},{"key":"1488_CR104","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","volume":"14","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kasap C, Weier C et al (2008b) Transient potent BCR\u2013ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 14:485\u2013493","journal-title":"Cancer Cell"},{"key":"1488_CR105","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"NP Shah","year":"2010","unstructured":"Shah NP, Kim DW, Kantarjian H et al (2010) Potent, transient inhibition of BCR\u2013ABL with dasatinib 100\u00a0mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 95:232\u2013240","journal-title":"Haematologica"},{"key":"1488_CR106","doi-asserted-by":"crossref","unstructured":"Shah NP, Cortes JE, Schiffer CA et al (2011) Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. [abstract 6512]. J Clin Oncol 29","DOI":"10.1200\/jco.2011.29.15_suppl.6512"},{"key":"1488_CR107","doi-asserted-by":"crossref","unstructured":"Shah NP, Kantarjian H, Kim DW et al (2012) Six-year follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia receiving dasatinib. [abstract 6506]. J Clin Oncol 30","DOI":"10.1200\/jco.2012.30.15_suppl.6506"},{"key":"1488_CR108","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1200\/JCO.2006.08.9128","volume":"24","author":"S Soverini","year":"2006","unstructured":"Soverini S, Martinelli G, Colarossi S et al (2006) Presence or the emergence of a F317L BCR\u2013ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. J Clin Oncol 24:e51\u2013e52","journal-title":"J Clin Oncol"},{"key":"1488_CR109","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S1470-2045(07)70078-5","volume":"8","author":"S Soverini","year":"2007","unstructured":"Soverini S, Martinelli G, Colarossi S (2007a) Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR\u2013ABL mutants in Ph+\u00a0ALL. Lancet Oncol 8:273\u2013274","journal-title":"Lancet Oncol"},{"key":"1488_CR110","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3324\/haematol.10822","volume":"92","author":"S Soverini","year":"2007","unstructured":"Soverini S, Colarossi S, Gnani A et al (2007b) Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR\u2013ABL kinase domain. Haematologica 92:401\u2013404","journal-title":"Haematologica"},{"key":"1488_CR111","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","volume":"114","author":"S Soverini","year":"2009","unstructured":"Soverini S, Gnani A, Colarossi S et al (2009) Philadelphia-positive patients who already harbor imatinib-resistant Bcr\u2013Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 114:2168\u20132171","journal-title":"Blood"},{"key":"1488_CR112","unstructured":"Sprycel\u00ae (dasatinib) capsules [prescribing information] 2013. Princeton, NJ: Bristol-Myers Squibb Company"},{"key":"1488_CR113","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531\u20132541","journal-title":"N Engl J Med"},{"key":"1488_CR114","unstructured":"Tasigna (nilotinib) capsules [prescribing information] 2013 East Hanover, NJ: Novartis Pharmaceuticals Corporation"},{"key":"1488_CR115","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski JS, Newitt JA, Chang CY et al (2006) The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 66:5790\u20135797","journal-title":"Cancer Res"},{"key":"1488_CR116","doi-asserted-by":"publisher","first-page":"18292","DOI":"10.1074\/jbc.M801337200","volume":"283","author":"N Vajpai","year":"2008","unstructured":"Vajpai N, Strauss A, Fendrich G et al (2008) Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib\/nilotinib and dasatinib. J Biol Chem 283:18292\u201318302","journal-title":"J Biol Chem"},{"key":"1488_CR117","first-page":"85","volume":"5","author":"X Wang","year":"2013","unstructured":"Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP (2013) Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure\u2014response analysis of a Phase III study. Clin Pharmacol 5:85\u201397","journal-title":"Clin Pharmacol"},{"key":"1488_CR118","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr\u2013Abl. Cancer Cell 7:129\u2013141","journal-title":"Cancer Cell"},{"key":"1488_CR119","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","volume":"110","author":"DL White","year":"2007","unstructured":"White DL, Saunders VA, Dang P et al (2007) Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110:4064\u20134072","journal-title":"Blood"},{"key":"1488_CR120","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.immunol.22.012703.104753","volume":"22","author":"S Wong","year":"2004","unstructured":"Wong S, Witte ON (2004) The BCR\u2013ABL story: bench to bedside and back. Annu Rev Immunol 22:247\u2013306","journal-title":"Annu Rev Immunol"},{"key":"1488_CR121","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","volume":"77","author":"T Zhou","year":"2011","unstructured":"Zhou T, Commodore L, Huang WS et al (2011) Structural mechanism of the pan-BCR\u2013ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77:1\u201311","journal-title":"Chem Biol Drug Des"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-013-1488-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-013-1488-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-013-1488-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-013-1488-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:07:35Z","timestamp":1630544855000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-013-1488-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,13]]},"references-count":121,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1488"],"URL":"https:\/\/doi.org\/10.1007\/s00432-013-1488-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,13]]},"assertion":[{"value":"22 July 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}